RxDoctor Payments Data

Boyd Southwick, DO

Family Medicine · Idaho Falls, IDNPI 1578613337

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 626 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,579in general payments, 2019–2025

Across 626 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$682
  • Lilly USA, LLC$672
  • Boehringer Ingelheim$586
  • Novo Nordisk$519
  • Otsuka America Pharmaceutical, Inc.$430
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$9,551100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)132$2,190
Amgen(2 entities)52$682
Lilly USA, LLC60$672
Boehringer Ingelheim33$586
Novo Nordisk38$519
Otsuka America Pharmaceutical, Inc.29$430
Astellas Pharma US Inc21$388
Antares Pharma, Inc.21$359
GSK24$333
Novartis15$253
Axsome Therapeutics, Inc.14$239
Teva Pharmaceuticals USA, Inc.16$227
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$180
Amarin Pharma, Inc.9$138
AstraZeneca9$136
Pfizer9$126
Vanda Pharmaceuticals Inc.4$117
Sunovion Pharmaceuticals Inc.8$113
Biocryst US Sales Co., LLC5$111
Bayer7$102
Merck6$100
Sanofi Pasteur Inc.4$91
Takeda Pharmaceuticals U.S.A., Inc.7$91
Corium, LLC9$89
Genentech USA, Inc.6$89
Boston Scientific5$85
Johnson & Johnson5$85
Corcept Therapeutics3$63
Shield Therapeutics Inc3$57
Esperion Therapeutics, Inc.4$56
Ionis Pharmaceuticals, Inc.2$49
Ironshore Pharmaceuticals Inc.3$47
Dexcom, Inc.2$45
Acadia Pharmaceuticals Inc3$44
Phathom Pharmaceuticals, Inc.3$43
Neurocrine Biosciences, Inc.2$41
Mylan Specialty L.p.2$40
Arbor Pharmaceuticals, Inc.3$35
Sanofi-aventis U.S. LLC3$34
Neurelis, Inc.2$34
Shire North American Group Inc2$30
Biocryst Pharmaceuticals, Inc.1$30
Eisai Inc.2$29
Pharming Healthcare, Inc.2$28
Impel Pharmaceuticals Inc.2$26
Adlon Therapeutics L.p.2$26
Lundbeck LLC1$24
Alnylam Pharmaceuticals Inc.1$21
Aimmune Therapeutics, Inc.1$19
Ultragenyx Pharmaceutical Inc.1$18
Ipsen Biopharmaceuticals, Inc1$18
Seqirus USA Inc1$18
Gilead1$17
Si-bone, Inc.1$17
CSL Behring1$16
Edwards Lifesciences1$16
Regeneron Healthcare Solutions, Inc.1$15
Xeris Pharmaceuticals, Inc.1$15
Tris Pharma Inc1$14
Therapeuticsmd, Inc.1$14

How this compares

$9,579 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$144,337
Medicare patients
304
Services billed
2,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CinryzeC1 Esterase Inhibitor12$1,881,022
EliquisApixaban96$80,038
TrulicityDulaglutide54$75,013
JardianceEmpagliflozin44$40,838
MounjaroTirzepatide21$22,651
OzempicSemaglutide22$18,634
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,993
VraylarCariprazine Hcl11$16,113
XareltoRivaroxaban29$14,139
Spiriva RespimatTiotropium Bromide21$11,145
FarxigaDapagliflozin Propanediol16$10,814
Aimovig AutoinjectorErenumab-Aooe12$9,146
Levothyroxine Sodium717$6,554
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$5,820
Celecoxib115$4,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Cinryze$91$1,881,02212 claims
Lilly USA, LLCTrulicity, Mounjaro$672$97,66475 claims
PfizerEliquis$126$80,03896 claims
Boehringer IngelheimJardiance, Spiriva Respimat$586$51,98465 claims
Novo NordiskOzempic$519$18,63422 claims
GSKTrelegy Ellipta$333$16,99319 claims
AbbVieVraylar$2,190$16,11311 claims
Johnson & JohnsonXarelto$85$14,13929 claims
AstraZenecaFarxiga$136$10,81416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.

Other family medicine in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →